Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease

Neurochemistry International

Volumn 108, Issue , 2017, Pages 355-360

  Lista, Simone ^a   Toschi, Nicola ^b,c,d   Baldacci, Filippo ^a,e   Zetterberg, Henrik ^f,g   Blennow, Kaj ^f,h   Kilimann, Ingo ⁱ   Teipel, Stefan J ⁱ   Cavedo, Enrica ^a,j   dos Santos, Antonio Melo ^a   Epelbaum, Stéphane ^a   Lamari, Foudil ^k   Dubois, Bruno ^a   Floris, Roberto ^b   Garaci, Francesco ^b,l   Hampel, Harald ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF PISA   (Italy)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h ROYAL SWEDISH ACADEMY OF SCIENCES   (Sweden)

ⁱ UNIVERSITY OF ROSTOCK   (Germany)

^j IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^l Casa di Cura S Raffaele   (Italy)

more..

Author keywords

Alzheimer's disease pathophysiology; Biomarkers; Cerebrospinal fluid; Frontotemporal dementia; Mild cognitive impairment; Neurofilament light chain protein

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; NEUROFILAMENT PROTEIN; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); NEUROFILAMENT PROTEIN L; PEPTIDE FRAGMENT;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; CLASSIFICATION; CLINICAL TRIAL; COHORT ANALYSIS; MIDDLE AGED; PILOT STUDY; RETROSPECTIVE STUDY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROFILAMENT PROTEINS; PEPTIDE FRAGMENTS; PILOT PROJECTS; RETROSPECTIVE STUDIES; TAU PROTEINS;

EID: 85019840320     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2017.05.010     Document Type: Article

References (25)

1. Albert, M.S., DeKosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., Gamst, A., Holtzman, D.M., Jagust, W.J., Petersen, R.C., Snyder, P.J., Carrillo, M.C., Thies, B., Phelps, C.H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. J. Alzheimers Assoc. 7 (2011), 270–279, 10.1016/j.jalz.2011.03.008.
2. Bajo, M., Yoo, B.C., Cairns, N., Gratzer, M., Lubec, G., Neurofilament proteins NF-L, NF-M and NF-H in brain of patients with Down syndrome and Alzheimer's disease. Amino Acids 21 (2001), 293–301.
3. Baldacci, F., Lista, S., Garaci, F., Bonuccelli, U., Toschi, N., Hampel, H., Biomarker-guided classification scheme of neurodegenerative diseases. J. Sport Health Sci., 2016, 10.1016/j.jshs.2016.08.007.
4. Baldacci, F., Toschi, N., Lista, S., Zetterberg, H., Blennow, K., Kilimann, I., Teipel, S., Cavedo, E., Dos Santos, A.M., Epelbaum, S., Lamari, F., Dubois, B., Floris, R., Garaci, F., Bonuccelli, U., Hampel, H., Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease. Alzheimers Dement. J. Alzheimers Assoc., 2017, 10.1016/j.jalz.2017.01.021.
5. Dubois, B., Feldman, H.H., Jacova, C., Hampel, H., Molinuevo, J.L., Blennow, K., DeKosky, S.T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G.B., Fox, N.C., Galasko, D., Habert, M.-O., Jicha, G.A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L.C., Vellas, B., Visser, P.J., Schneider, L., Stern, Y., Scheltens, P., Cummings, J.L., Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 13 (2014), 614–629, 10.1016/S1474-4422(14)70090-0.
6. Hyman, B.T., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Carrillo, M.C., Dickson, D.W., Duyckaerts, C., Frosch, M.P., Masliah, E., Mirra, S.S., Nelson, P.T., Schneider, J.A., Thal, D.R., Thies, B., Trojanowski, J.Q., Vinters, H.V., Montine, T.J., National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. J. Alzheimers Assoc. 8 (2012), 1–13, 10.1016/j.jalz.2011.10.007.
7. Jack, C.R., Bennett, D.A., Blennow, K., Carrillo, M.C., Feldman, H.H., Frisoni, G.B., Hampel, H., Jagust, W.J., Johnson, K.A., Knopman, D.S., Petersen, R.C., Scheltens, P., Sperling, R.A., Dubois, B., A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology, 2016, 10.1212/WNL.0000000000002923.
8. Landqvist Waldö, M., Frizell Santillo, A., Passant, U., Zetterberg, H., Rosengren, L., Nilsson, C., Englund, E., Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia. BMC Neurol., 13, 2013, 54, 10.1186/1471-2377-13-54.
9. Lee, M.K., Xu, Z., Wong, P.C., Cleveland, D.W., Neurofilaments are obligate heteropolymers in vivo. J. Cell Biol. 122 (1993), 1337–1350.
10. Liu, Q., Xie, F., Siedlak, S.L., Nunomura, A., Honda, K., Moreira, P.I., Zhua, X., Smith, M.A., Perry, G., Neurofilament proteins in neurodegenerative diseases. Cell. Mol. Life Sci. CMLS 61 (2004), 3057–3075, 10.1007/s00018-004-4268-8.
11. Mattsson, N., Insel, P.S., Palmqvist, S., Portelius, E., Zetterberg, H., Weiner, M., Blennow, K., Hansson, O., Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Mol. Med., 2016, 10.15252/emmm.201606540.
12. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34 (1984), 939–944.
13. Meeter, L.H., Dopper, E.G., Jiskoot, L.C., Sanchez-Valle, R., Graff, C., Benussi, L., Ghidoni, R., Pijnenburg, Y.A., Borroni, B., Galimberti, D., Laforce, R.J., Masellis, M., Vandenberghe, R., Ber, I.L., Otto, M., van Minkelen, R., Papma, J.M., Rombouts, S.A., Balasa, M., Öijerstedt, L., Jelic, V., Dick, K.M., Cash, D.M., Harding, S.R., Jorge Cardoso, M., Ourselin, S., Rossor, M.N., Padovani, A., Scarpini, E., Fenoglio, C., Tartaglia, M.C., Lamari, F., Barro, C., Kuhle, J., Rohrer, J.D., Teunissen, C.E., van Swieten, J.C., Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann. Clin. Transl. Neurol. 3 (2016), 623–636, 10.1002/acn3.325.
14. Nakamura, Y., Hasimoto, R., Kashiwagi, Y., Miyamae, Y., Shinosaki, K., Nishikawa, T., Hattori, H., Kudo, T., Takeda, M., Abnormal distribution of neurofilament L in neurons with Alzheimer's disease. Neurosci. Lett. 225 (1997), 201–204.
15. Neary, D., Snowden, J.S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P.H., Albert, M., Boone, K., Miller, B.L., Cummings, J., Benson, D.F., Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51 (1998), 1546–1554.
16. Norgren, N., Karlsson, J.E., Rosengren, L., Stigbrand, T., Monoclonal antibodies selective for low molecular weight neurofilaments. Hybrid. Hybridomics 21 (2002), 53–59.
17. Norgren, N., Rosengren, L., Stigbrand, T., Elevated neurofilament levels in neurological diseases. Brain Res. 987 (2003), 25–31.
18. Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., Wu, E., Dakin, K., Petzold, M., Blennow, K., Zetterberg, H., CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol., 2016, 10.1016/S1474-4422(16)00070-3.
19. Scherling, C.S., Hall, T., Berisha, F., Klepac, K., Karydas, A., Coppola, G., Kramer, J.H., Rabinovici, G., Ahlijanian, M., Miller, B.L., Seeley, W., Grinberg, L.T., Rosen, H., Meredith, J., Boxer, A.L., Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann. Neurol. 75 (2014), 116–126, 10.1002/ana.24052.
20. Schlaepfer, W.W., Lynch, R.G., Immunofluorescence studies of neurofilaments in the rat and human peripheral and central nervous system. J. Cell Biol. 74 (1977), 241–250.
21. Sjögren, M., Blomberg, M., Jonsson, M., Wahlund, L.O., Edman, A., Lind, K., Rosengren, L., Blennow, K., Wallin, A., Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J. Neurosci. Res. 66 (2001), 510–516.
22. Sjögren, M., Rosengren, L., Minthon, L., Davidsson, P., Blennow, K., Wallin, A., Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 54 (2000), 1960–1964.
23. Wang, J., Tung, Y.C., Wang, Y., Li, X.T., Iqbal, K., Grundke-Iqbal, I., Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. FEBS Lett. 507 (2001), 81–87.
24. Xia, J., Broadhurst, D.I., Wilson, M., Wishart, D.S., Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabol. Off. J. Metabol. Soc. 9 (2013), 280–299, 10.1007/s11306-012-0482-9.
25. Zetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J.Q., Portelius, E., Shaw, L.M., Weiner, M.W., Blennow, K., Alzheimer's disease neuroimaging initiative. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurol. 73 (2016), 60–67, 10.1001/jamaneurol.2015.3037.